Study selection The criteria for including studies in this meta-analysis were as follows: (1) (i) randomized controlled trials (RCTs) comparing different AOMs with placebo, including glucagon-like peptide 1 receptor agonist (GLP-1 RA), dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RAs, GLP-1 and glucagon receptor (GCGR) dual-agonist, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and bimagrumab
2020;33(4):e13790
Use is limited to research institutions, laboratories, or licensed researchers operating within lawful regulatory frameworks
GLP-1 receptor agonists, as a drug class, have been in clinical use since 2005, and semaglutide has been licensed since 2017
H 2 O 2 level is proportional to the luminescent signal which was measured by a multi-mode microplate reader (FLUOstar Omega)
Users may notice: Improved control over appetite and cravings More stable energy levels throughout the day Reduced tendency to snack between meals Gradual support for healthy weight management Better alignment with balanced eating habits Results vary depending on lifestyle, diet, and individual metabolism, but Levia is designed for gradual and sustainable support rather than rapid change
